Systematic reviews of randomized controlled trials of cannabinoid products in chronic pain conditions and for symptoms associated with multiple sclerosis: what do they tell us?-Reference-Cited by-同舟云学术

Systematic reviews of randomized controlled trials of cannabinoid products in chronic pain conditions and for symptoms associated with multiple sclerosis: what do they tell us?

Published:2022-04-03 Issue:4 Volume:15 Page:415-431
ISSN:1751-2433
Container-title:Expert Review of Clinical Pharmacology
language:en
Short-container-title:Expert Review of Clinical Pharmacology

Author:

Vila Silván Carlos¹,Vaney Claude²,Dykukha Igor³^ORCID

Affiliation:

1. Global Medical Affairs, Almirall S.A, Barcelona, Spain

2. Clinique de Réhabilitation, HFR Meyriez-MurtenMédecin-Adjoint, Meyriez, Switzerland

3. Medical Affairs, Almirall Hermal GmbH, Reinbek, Germany

Funder

Almirall S.A.

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17512433.2022.2088501

Reference68 articles.

1. Cannabinoids: Medical implications

2. A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol

3. Blurred Boundaries: The Therapeutics and Politics of Medical Marijuana

4. Cannabinoids and Pain: New Insights From Old Molecules

5. Electronic Medicines Compendium. Sativex oromucosal spray: summary of product characteristics. [cited 2021 Jul 19]; Available from: https://www.medicines.org.uk/emc/product/602/smpc#gref

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CBD as a cure‐all? The impacts of state‐level legalization of prescription cannabidiol (CBD) on opioid prescriptions;Southern Economic Journal;2023-10-26